[18F] Flourothymidine (FLT) PET/CT Imaging for Gynecologic Cancers
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cervical Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/25/2017 |
| Start Date: | February 2014 |
| End Date: | February 2017 |
The purpose of this study is to determine the effect of specific bone marrow maps developed
with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton
beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a
history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment,
one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take
place in the Department of Radiation Oncology.
with18F-FLT PET/CT imaging on the ability to spare proliferating bone marrow using proton
beam radiotherapy compared to IMRT. Participants will be 18 years of age or old with a
history of gynecologic cancer. Subjects will undergo 3 FLT-PET scans (one before treatment,
one during the course of RT, and one 2-5 weeks after initiation of RT). Scans will take
place in the Department of Radiation Oncology.
Inclusion Criteria:
- Participants will be 18 years of age or older
- History of gynecologic cancer.
- Recommended to undergo IMRT or PBT of the pelvis with concurrent chemotherapy
- Female participants of child-bearing potential must have a negative urine or serum
pregnancy test at the time of the screening visit.
- Participants must be informed of the investigational nature of this study and provide
written informed consent in accordance with institutional and federal guidelines
prior to study specific procedures.
- Participants must be willing and able to comply with scheduled visits and imaging
procedures in the opinion of the investigator or treating physician.
Exclusion Criteria
- Females who are pregnant or breast feeding at the time of screening will not be
eligible for this study.
- Inability to tolerate imaging procedures in the opinion of the investigator or
treating physician
- Serious or unstable medical or psychological conditions that, in the opinion of the
investigator would compromise the subjects safety or successful participation in the
study.
- Unwilling or unable to provide informed consent
We found this trial at
1
site
3400 Civic Center Blvd
Philadelphia, Pennsylvania 19104
Philadelphia, Pennsylvania 19104
(215) 662-6065
Principal Investigator: Lilie Lin, MD
Phone: 855-216-0098
Abramson Cancer Center of the University of Pennsylvania The Abramson Cancer Center of the University...
Click here to add this to my saved trials
